Authors

Latest:

Dr. Puertas‐Martinez on Carfilzomib and Dexamethasone plus Cyclophosphamide in Multiple Myeloma

Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.

Carmen Guerra, MD, MSCE, FACP

Latest:

Dr Guerra on the Implications of a Study on Prostate Cancer Screening in Diverse Populations

Carmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.

Andrew Matthews, MD

Latest:

Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AML

Andrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.

Meredith Pelster, MD, MSCI

Latest:

Raising the Bar for KRAS G12C+ Colorectal Cancer Treatment

With 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.

Mayo Clinic

Latest:

Researchers Resolve Uncertainty in BRCA2 Testing, Improving Cancer Risk Assessment and Patient Care

Findings will help identify patients with breast, ovarian, pancreatic, or prostate cancer who may benefit from targeted therapies.

Mitul Gandhi, MD

Latest:

Dr. Gandhi on Key Interim Results From the SGN35-027 Trial in Hodgkin Lymphoma

Mitul Gandhi, MD, discusses key findings from part C of the phase 2 SGN35-027 trial in Hodgkin lymphoma.

Mitchell S. Cairo, MD

Latest:

VOD: Ensuring Best Outcomes

Experts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.

Gaël Roué, PhD

Latest:

Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL Models

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Kaveh Zakeri, MD, MAS

Latest:

Treatment Paradigms Are Shifting for Locally Advanced HPV-Positive Head and Neck Cancers

A personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.

Peter Riedell

Latest:

Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.

Anna Woloszynska, PhD

Latest:

Dr. Woloszynska on the Role of Community Outreach in Addressing Disparities in Prostate Cancer

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Casey M. Cosgrove, MD

Latest:

Dr Cosgrove on the FDA Approval of Mirvetuximab Soravtansine for Frα+ Ovarian Cancer

Casey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.

Nisha A. Mohindra, MD

Latest:

Dr Mohindra on Updates in SCLC Management

Nisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.

Andrew Hantel, MD

Latest:

Dr Hantel on Eligibility Criteria Associated With Racial/Ethnic Disparities in Clinical Trial Enrollment in AML

Andrew Hantel, MD, discusses eligibility criteria associated with racial and ethnic disparities in clinical trial participation in acute myeloid leukemia.

Ahmed Megahed, MBBCh

Latest:

Megahed on the Effects of NGS on First-Line Treatment Decisions in NSCLC

Ahmed Megahed, MBBCh, discusses the rationale for investigating the effects of next-generation sequencing on first-line treatment decisions for patients with stage IV non–small cell lung cancer.

Megan Hitchins, PhD

Latest:

Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial Cancers

Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.

Onyee Chan, MD

Latest:

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Ariel Grajales-Cruz, MD

Latest:

Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Moritz Fürstenau MD

Latest:

Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLL

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Natasha B Hunter, MD

Latest:

Dr. Hunter on the Role of 18F-FES-PET Imaging in Triple-Positive Breast Cancer

Natasha B Hunter, MD, discusses the utility of 18F-Fluoroestradiol PET imaging for patients with estrogen receptor–positive and HER2-positive breast cancer.